Abstract | BACKGROUND: METHODS: RESULTS: Baseline demographic characteristics and risk factors for nephrolithiasis were similar in the placebo and treatment arms. Estrogen therapy was associated with a significant increase in nephrolithiasis risk from 34 to 39 cases per 10 000 person-years (hazard ratio, 1.21; 95% confidence interval, 1.03-1.44). Censoring data from women when they ceased to adhere to study medication increased the hazard ratio to 1.39 (95% confidence interval, 1.08-1.78). The increased nephrolithiasis risk was independent of progestin coadministration, and effects did not vary significantly according to prerandomization history of nephrolithiasis. CONCLUSIONS: These data suggest that estrogen therapy increases the risk of nephrolithiasis in healthy postmenopausal women. These findings should be considered in decision making regarding postmenopausal estrogen use. The mechanisms underlying this higher susceptibility remain to be determined. Trial Registration clinicaltrials.gov Identifier: NCT0000611.
|
Authors | Naim M Maalouf, Alicia H Sato, Brian J Welch, Barbara V Howard, Barbara B Cochrane, Khashayar Sakhaee, John A Robbins |
Journal | Archives of internal medicine
(Arch Intern Med)
Vol. 170
Issue 18
Pg. 1678-85
(Oct 11 2010)
ISSN: 1538-3679 [Electronic] United States |
PMID | 20937929
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
|
Chemical References |
- Drug Combinations
- Estrogens
- Estrogens, Conjugated (USP)
- Prempro
- Medroxyprogesterone Acetate
|
Topics |
- Aged
- Clinical Trials as Topic
- Confidence Intervals
- Drug Combinations
- Drug Therapy, Combination
- Estrogen Replacement Therapy
(adverse effects)
- Estrogens
(administration & dosage, adverse effects)
- Estrogens, Conjugated (USP)
(administration & dosage, adverse effects)
- Female
- Humans
- Hysterectomy
- Incidence
- Medroxyprogesterone Acetate
(administration & dosage, adverse effects)
- Middle Aged
- Nephrolithiasis
(chemically induced)
- Odds Ratio
- Postmenopause
- Risk Assessment
- Risk Factors
- United States
|